Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia
- 7 September 2018
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 37 (2), 117-128
- https://doi.org/10.1002/hon.2539
Abstract
The finding of an IgM monoclonal gammopathy often represents a diagnostic challenge. In fact, there are many pathological disorders associated with this condition, each of which has distinctive characteristics and requires specific clinical, instrumental, and laboratory assessments to set the appropriate treatment. This review has two aims. Firstly, to provide a framework of the broad spectrum of IgM‐associated disorders: (1) monoclonal gammopathy of undetermined significance (MGUS); (2) Waldenström macroglobulinemia (WM); (3) IgM‐related disorders (among which hyperviscosity syndrome, light chain amyloidosis, cold agglutinin disease, cryoglobulinaemia, IgM neuropathy, Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome, Castleman disease); (4) IgM‐secreting multiple myeloma (IgM‐MM); and (5) other lymphoproliferative disorders which may be associated with IgM (such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and B‐cell non Hodgkin lymphoma). Secondly, to give a detailed insight regarding diagnosis and treatment of WM.This publication has 85 references indexed in Scilit:
- Temporal and geographic variations of Waldenstrom macroglobulinemia incidenceCancer, 2011
- Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemiaCancer, 2011
- Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter StudyJournal of Clinical Oncology, 2010
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180Journal of Clinical Oncology, 2009
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009
- Thalidomide and rituximab in Waldenstrom macroglobulinemiaBlood, 2008
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Renal Lesions Associated with IgM-Secreting Monoclonal ProliferationsClinical Journal of the American Society of Nephrology, 2008
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaThe New England Journal of Medicine, 2007
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003